Autor: |
Jung-An Lin, Yeu-Chin Chen, Shin-Nan Cheng, Peng-Jen Chen, Heng-Cheng Chu, Tsai-Yuan Hsieh, Yu-Lueng Shih |
Jazyk: |
angličtina |
Rok vydání: |
2014 |
Předmět: |
|
Zdroj: |
Journal of the Formosan Medical Association, Vol 113, Iss 10, Pp 727-733 (2014) |
Druh dokumentu: |
article |
ISSN: |
0929-6646 |
DOI: |
10.1016/j.jfma.2013.10.010 |
Popis: |
Chronic hepatitis C virus (HCV) infection is a major cause of morbidity and mortality in patients with hemophilia. However, the efficacy and safety of pegylated interferon (PEG-IFN) plus ribavirin (RBV) for hemophilic patients with chronic HCV infection in Taiwan are still unknown. The aim of this study is to report the efficacy and safety of PEG-IFN plus RBV in a single center in Taiwan. Methods: In an open-label single-treatment one-arm cohort study, 12 hemophilic patients with elevated alanine aminotransferase level more than two times the upper limit of normal for more than 3 months received 180 μg/week of PEG-IFN-α-2a plus RBV 1000–1200 mg/day at a cut-off value of 75 kg. The duration of treatment was 48 weeks for patients with HCV Genotype 1/4 infection and 24 weeks for patients with HCV Genotype 2/3 infection. Efficacy of therapy was expressed as sustained virological response (SVR). Results: Eight patients achieved SVR (66.7%). The SVR rates were 57%, 100%, 100%, and 0% for patients with HCV Genotypes 1, 2, 3, and 4 infection, respectively. Adverse events (AEs) developed in 10 patients (83.3%). Severe thrombocytopenia developed in one patient. However, the patient did not suffer from severe bleeding. Conclusion: Our study shows that the SVR rates are similar in hemophilic and nonhemophilic patients with chronic HCV infection who receive PEG-IFN-α-2a plus RBV in Taiwan. The rate of AEs also resembled other studies in nonhemophilic patients in Taiwan. No patient suffered from severe bleeding. However, large-scale, well-conducted studies are still needed to verify the treatment efficacy and safety. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|